2018 Jan;72(1):105-111
What to expect: Enhanced metabolic responses and visible weight loss
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Follow-Up & Adjustment Protocols are monitored and adjusted based on your response
We did not find a public clinical trial designed to establish the side effect rate of the finished Luxxe White Ultima formula
One transdermal patch berberine and cinnamon extract marketed for appetite and craving control recurs across several pages and several websites with cosmetically altered titles (GLP-1 Support Patches, New GLP-1 Patches, GLP-1 Lifestyle Support Patches, GLP-1 Herbal Support Patch, and others), at prices ranging from 149 to 669 for what appears to be an identical product in different quantities
